Key findings included:
- A median prostate-specific antigen (PSA) reduction of 94.9% (nadir 0.34 ng/ml).
- Of 115 patients treated, 110 (95.7%) achieved the PSA reduction endpoint.
- A median perfused prostate volume of patients that decreased from 41 cc to 4 cc.
- A low rate (7%) of serious (Grade 3) adverse events, which all resolved.
- At 12 months, there was 99.1% (111 out of 112) preservation of urinary continence (≤1 pad/day), and a 96.2% rate of leak-free continence (leak <1 time/day).
- At 12 months, only 23.5% of the patients had moderate erectile dysfunction (oral medication indicated), and no patient experienced severe erectile dysfunction (oral medication not helpful).
- Among 68 men with pre-treatment intermediate-risk Gleason Score (GS) 7 disease, 54 (79.4%) were free of GS7 disease on one-year biopsy.
- Of the 111 men with one-year biopsy data, 72 (64.9%) had a complete histological response with no evidence of any cancer, and 16 (14.4%) had low-volume GS6 biologically-insignificant disease.
See the Profound Medical TACT Data Press Release >
See the AUA Abstract Data >
Medpage Today | Ultrasound Therapy for Prostate Ca Yields High PSA Response 5/7/19